MRKMerck Sharp & Dohme LLCRunning, no new patients
A Study of Belzutifan (MK-6482) Versus Everolimus in Participants With Advanced Renal Cell Carcinoma (MK-6482-005)
Carcinoma, Renal Cell
2Calmworry score, out of 100
No strong warning signs right now. The score counts warning signs; it is not a prediction.
Why this score
- +1.9
5 insiders sold shares within a month
Since Aug 13, 2026 · was worth 5, fading over time
Worry score2
Score over time
- Stage
- Phase 3
- Patients
- 755 (final count)
- Started
- Feb 27, 2020
- Main results expected
- Apr 15, 2024
- Fully finished
- Oct 14, 2026
- Results posted
- Apr 29, 2025
What counts as success
The trial's main goal(s), called the “primary outcome.”
Progression-free Survival (PFS) Per Response Criteria in Solid Tumors Version 1.1 (RECIST 1.1) as Assessed by Blinded Independent Central Review (BICR)
Measured over: Up to approximately 39 months
Overall Survival (OS)
Measured over: Up to approximately 49 months
Changes Tremor has spotted
No changes since Tremor started watching this trial.
Show details (technical version)
Score inputs
- insider_selling_cluster: base 5, now 1.9, since 2026-08-13, fades (half-life)
Raw record changes
- none yet
Trial ID NCT04195750 · record last updated 2026-10-20 · checked 2026-11-09 15:47 UTC